Sterile Focus Brands and third party manufacturing are the most material contributors to revenue in this region.
The active pharmaceutical ingredient (“API”) site in The Netherlands, supported by its satellite operation at Sioux City, in the United States supplies APIs worldwide. We provide a broad range of sterile medicines in Europe largely utilised in an acute hospital setting.
- The Developed Europe Injectable Thrombosis market was valued at
EUR1,9 billion as at March 2020.
- The EU5 (France, Germany, Italy, Spain, UK) propofol market was valued at
EUR372 million as at 31 December 2019.
Number of products launched:
Average staff turnover:
Number of product recalls:
Number of work-related fatalities:
|Number of permanent employees|
|Total||13 857||12 964||7|
|Regional Brands||1 784||1 905||(6)|
|Sterile Focus Brands||5 764||5 593||3|
|Anaesthetics Brands||2 677||2 346||14|
|Thrombosis Brands||3 087||3 247||(5)|
|Total Commercial Pharmaceuticals||7 548||7 498||1|
|Manufacturing||6 309||5 466||15|
|API||5 628||4 780||18|
Note: Commercial Pharmaceuticals revenue by customer geography and manufacturing revenue by place of manufacture.